Dicker Dror, Herskovitz Pearl, Katz Miryam, Atar Eli, Bachar Gil N
Department of Internal Medicine D, Rabin Medical Center (Golda Campus), Petah Tikva, Israel.
Isr Med Assoc J. 2010 Apr;12(4):199-202.
Obesity has become a major public health problem worldwide.
To examine the effect of orlistat in promoting weight loss and its specific effect on visceral adipose tissue and subcutaneous adipose tissue as evaluated by computed tomography.
A prospective case series study of 10 obese subjects was conducted. The 6 women and 4 men, age 50-67 years (mean 59 +/- 8 years), had a mean body mass index of 34.1 +/- 3.2 kg/m2. All subjects were prescribed a mildly hypocaloric diet (600 kcal/day deficit). In addition, all subjects were treated with orlistat 120 mg 3 times a day for 20.1 +/- 7 weeks.
The subjects had lost approximately 8.2 kg each, or 8.4% of their initial body weight. Mean body weight decreased from 98 +/- 13 to 89.8 +/- 13.6 kg at the last followup visit (P = 0.0001); mean BMI decreased from 34.1 +/- 3.2 to 30.3 +/- 3.9 kg/m2 (P = 0.0001), and mean waist circumference from 113.8 +/- 11.4 to 107.6 +/- 10 cm (P = 0.0006). Mean total abdominal adipose tissue volume, evaluated by computed tomography, decreased from 426 +/- 104.3 to 369.8 +/- 99.6 mm3 (P = 0.0001). Mean abdominal SAT volume decreased from 251.1 +/- 78.8 to 224 +/- 81.1 mm3 (P = 0.006), and mean abdominal VAT volume decreased from 176 +/- 76.7 to 141.6 +/- 67 mm3 (P = 0.0001). Thus, the total abdominal adipose tissue volume for the whole group decreased by 15.4%, and most of this decrease was attributable to the reduction in VAT (24.8%) as opposed to SAT (only 12% reduction) (P = 0.03). The weight reduction that occurred during the study was accompanied by a statistically significant reduction in levels of total cholesterol, low density lipoprotein-cholesterol, triglycerides, and fasting blood glucose.
Our results demonstrate the effect of orlistat in reducing human visceral adipose tissue as evaluated by CT. The benefit of the treatment is further supported by the statistically significant reduction in cardiovascular risk factors.
肥胖已成为全球主要的公共卫生问题。
通过计算机断层扫描评估奥利司他在促进体重减轻方面的效果及其对内脏脂肪组织和皮下脂肪组织的具体作用。
对10名肥胖受试者进行前瞻性病例系列研究。6名女性和4名男性，年龄50 - 67岁（平均59±8岁），平均体重指数为34.1±3.2kg/m²。所有受试者均采用轻度低热量饮食（每天热量 deficit 600千卡）。此外，所有受试者每天3次服用120mg奥利司他，持续20.1±7周。
受试者每人减重约8.2kg，占初始体重的8.4%。最后一次随访时平均体重从98±13kg降至89.8±13.6kg（P = 0.0001）；平均体重指数从34.1±3.2降至30.3±3.9kg/m²（P = 0.0001），平均腰围从113.8±11.4降至107.6±10cm（P = 0.0006）。通过计算机断层扫描评估，平均腹部总脂肪组织体积从426±104.3降至369.8±99.6mm³（P = 0.0001）。平均腹部皮下脂肪组织体积从251.1±78.8降至224±81.1mm³（P = 0.006），平均腹部内脏脂肪组织体积从176±76.7降至141.6±67mm³（P = 0.0001）。因此，整个组的腹部总脂肪组织体积减少了15.4%，其中大部分减少归因于内脏脂肪组织的减少（24.8%），而非皮下脂肪组织（仅减少12%）（P = 0.03）。研究期间发生的体重减轻伴随着总胆固醇、低密度脂蛋白胆固醇、甘油三酯和空腹血糖水平的统计学显著降低。
我们的结果证明了奥利司他在通过CT评估减少人体内脏脂肪组织方面的效果。心血管危险因素的统计学显著降低进一步支持了该治疗的益处。
